AZD8075 Single Ascending Dose Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00787072
Recruitment Status : Terminated (After reports of turbidity in urine in 4 of 8 volunteers in the 4th cohort, the study was halted temporarily.)
First Posted : November 7, 2008
Last Update Posted : December 2, 2010
Information provided by:

November 6, 2008
November 7, 2008
December 2, 2010
October 2008
January 2009   (Final data collection date for primary outcome measure)
Safety variables (ECG, adverse events, blood pressure, pulse, body temp, safety lab) [ Time Frame: Frequent sampling occasions during study days ]
Same as current
Complete list of historical versions of study NCT00787072 on Archive Site
PK variables [ Time Frame: Frequent sampling occasions during study days ]
Same as current
Not Provided
Not Provided
AZD8075 Single Ascending Dose Study
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD8075 in Healthy Male Volunteers
The aim of this study is to assess the safety, tolerability and pharmacokinetics of single ascending oral doses of AZD8075 in healthy male volunteers
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Healthy Volunteers
  • Drug: AZD8075
    Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
  • Drug: Placebo
    Oral suspension
  • Experimental: 1
    Intervention: Drug: AZD8075
  • Placebo Comparator: 2
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
January 2009
January 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provision of signed, written and dated informed consent prior to any study specific procedures.
  • Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg.
  • Be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for >6 months prior to study start.

Exclusion Criteria:

  • Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the result of the study, or the subject's ability to participate
  • Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs (vital signs (ie, supine BP and pulse) or ECG at baseline, which, in the opinion of the investigator, may put the subject at risk.
  • Participation in another investigational drug study within 3 months before Visit 2 or participation in a method development study (no drug) 1 month prior to Visit 2
Sexes Eligible for Study: Male
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Christer Hultquist, Medical Science Director, AstraZeneca R&D Lund, Sweden
Not Provided
Study Director: Eva Pettersson AstraZeneca R&D, Lund, Sweden
Principal Investigator: Wolfgang Kühn Quintiles, Uppsala, Sweden
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP